Previous studies have shown the involvement of IGF2BP2 gene polymorphism in attenuating the first phase of glucose-stimulated insulin secretion based on hyperglycaemic clamps, and the regulation of pancreatic β-cell function in Type 2 diabetes mellitus (T2DM) patients [16]. The gene discussed is IGF2BP2; the disease is type 2 diabetes mellitus.